GSGuanglong Sun

Guanglong Sun

*This is an algorithmically generated author record based on publicly available information.

Guanglong Sun has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A unified language model bridging de novo and fragment-based 3D molecule design delivers potent CBL-B inhibitors for cancer treatment

    by Han Wang, Guanglong Sun, Bowen Zhang, Yang Wang, Bin Xi, Minjian Yang, Chuanyu Liu, Yuyang Ge, Fan Fan, Wei Feng, et al.

    The rational design of small molecules is central to drug discovery, yet current artificial intelligence (AI) methodologies for generating three-dimensional (3D) molecules are often siloed, focusing on either de novo design or fragment-based design. The lack of a holistic framework limits AI’s application across the complex and multi-step pipeline spanning from novel scaffold identification to lead compound optimization, and prevents AI from effectively learning from the entire process. Here, we introduce UniLingo3DMol, a language model for 3D molecular generation, empowered by fragment permutation-capable molecular representation alongside multi-stage and multi-task training strategy. This integrated design enables UniLingo3DMol to seamlessly span both de novo and fragment-retained molecular design, demonstrating superior performance over existing generation models in in silico evaluations across more than 100 diverse biological targets. We further leveraged UniLingo3DMol in the design of inhibitors targeting CBL-B, a crucial immune E3 ubiquitin ligase and attractive immunotherapy target. This strategy led to a lead compound demonstrating excellent in vitro activity and robust in vivo anti-tumor efficacy. Our findings establish UniLingo3DMol as a generalized and powerful platform, showing the strong potential to advance AI-driven drug discovery.


  • Open Access

    Pocket-based molecule generation with an SE(3)-equivariant language model leads to a potent and selective HPK1 inhibitor with in vivo efficacy

    by Bin Xi, Han Wang, Guanglong Sun, Bowen Zhang, Ruihan Mao, Yuyang Ge, Yang Wang, Jiangtao Zhang, Yiting Pan, Feng Zhou, et al.

    Deep learning shows promise in structure-based drug discovery, yet challenges persist in generating pharmacologically plausible molecules with valid 3D conformation and decent binding mode in the pocket. We introduce SE3-BiLingoMol, an SE(3)-equivariant Transformer for pocket-based 3D molecule generation, addressing two key limitations of existing language-model approaches. First, it uses Geometric Algebra Transformers for SE(3)-equivariant handling of continuous 3D coordinates. Second, a bidirectional attention mechanism mitigates conformational errors accumulated during autoregressive sampling. These innovations enable SE3-BiLingoMol to generate 2D drug-like, 3D geometrically valid molecules with superior binding modes. Validated on DUD-E dataset containing over 100 targets, the model achieved state-of-the-art performance in de novo design and optimization. We applied SE3-BiLingoMol to design potent and selective inhibitors for HPK1, a promising immunotherapy target. Through an iterative human-AI workflow, integrating AI generation with experimental validations (X-ray crystallography, bioassays), we identified Cmpd. 6. This novel tetracyclic compound demonstrates potent HPK1 inhibition, excellent cellular activity, favorable pharmacokinetics, and robust anti-tumor in vivo efficacy as monotherapy and with PD-1 blockade. Our work establishes a sophisticated generative AI framework for 3D molecule design and demonstrates its application in developing cancer immunotherapy. Highlights: ● SE(3)-Equivariant Language Model for Molecule Generation: We introduce a dual-channel SE(3)-equivariant language model that supports de novo molecule design and optimization, addressing key challenges in prior language model-based 3D molecule generation approaches. ● Discovery of Potent HPK1 Inhibitors: Application of this model led to the discovery of highly selective HPK1 inhibitors with robust in vivo efficacy, resulting in a promising lead compound. ● AI-Guided Rational Drug Development Paradigm: This work establishes a paradigm for AI-guided rational drug development, showcasing AI as a “co-pilot” that inspires drug designers with novel ideas in an “evidence-based context”.